↓ Skip to main content

Novel ALK inhibitors in clinical use and development

Overview of attention for article published in Journal of Hematology & Oncology, February 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Novel ALK inhibitors in clinical use and development
Published in
Journal of Hematology & Oncology, February 2015
DOI 10.1186/s13045-015-0122-8
Pubmed ID
Authors

Chaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, Muhammad Furqan, Varun Mittal, Shundong Cang, Delong Liu

Abstract

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 2%
Unknown 58 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 17%
Researcher 10 17%
Other 9 15%
Student > Bachelor 8 14%
Student > Ph. D. Student 7 12%
Other 11 19%
Unknown 4 7%
Readers by discipline Count As %
Medicine and Dentistry 15 25%
Agricultural and Biological Sciences 14 24%
Biochemistry, Genetics and Molecular Biology 11 19%
Chemistry 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Other 3 5%
Unknown 8 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2017.
All research outputs
#4,142,272
of 8,864,881 outputs
Outputs from Journal of Hematology & Oncology
#127
of 401 outputs
Outputs of similar age
#90,667
of 206,042 outputs
Outputs of similar age from Journal of Hematology & Oncology
#7
of 19 outputs
Altmetric has tracked 8,864,881 research outputs across all sources so far. This one has received more attention than most of these and is in the 52nd percentile.
So far Altmetric has tracked 401 research outputs from this source. They receive a mean Attention Score of 2.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,042 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.